National Institute for Health and Care Excellence

It’s the first time a NICE committee has reviewed the evidence behind the procedure which preserves the donor liver by pumping oxygenated blood through it using a machine for around two hours. This allows the liver to recover from damage while it is still in the donor's body. Doctors can also run tests during this time to check how well the liver is working before it is removed.

Endometriosis affects around 1 in 10 women of reproductive age in the UK, yet the average time to diagnosis is more than 9 years. NICE's draft early use healthtech guidance recommends Endosure and Endotest, 2 technologies that can be used in the NHS during a 3-year period while additional evidence is collected on how well they work.

People with polyendocrine metabolic ovarian syndrome (PMOS) should have their condition diagnosed sooner and be offered an annual review to monitor symptoms, treatment and long-term health risks, according to draft our guideline published for public consultation today. PMOS was until recently known as polycystic ovary syndrome (PCOS). The new name better reflects the wide-ranging hormonal, metabolic and reproductive effects of the condition.

Listen About this episode NICE has recommended teplizumab for NHS use — the first treatment to delay the onset of symptomatic type 1 diabetes by an average of nearly three years. In this episode, we speak to Lucy Chambers, Head of Research Impact and Communications at Diabetes UK, and Amy Norman, whose daughter Imogen accessed teplizumab through a managed access programme after being identified through the ELSA screening study.

We’ve recommended cemiplimab (also called Libtayo and made by Regeneron) as an option for adults with recurrent or metastatic cervical cancer that has got worse during or after they’ve had platinum-based chemotherapy, and who have not had treatment with a type of medicine called an immunotherapy. Around 90 adults a year are expected to be eligible for this treatment. Recurrent or metastatic cervical cancer has a substantial impact on length and quality of life.

Clinical trial evidence reviewed by an independent NICE committee shows that teplizumab can delay the onset of symptomatic type 1 diabetes by an average of nearly 3 years. Teplizumab is the disease-modifying therapy for type 1 diabetes and England is the first country in Europe to recommend it's use through a health technology appraisal.

Evelyn Otunbade is the moving and handling lead at London North West University Healthcare NHS Trust. She leads on safe moving and handling practices, moving and handling strategy, access to appropriate handling equipment, and develops and delivers training programmes to support staff competence. In this guest blog, she explains how she led implementation of a consistent slide sheet procurement strategy, using NICE’s ready-made evaluation to save her time and build a compelling case for change.

Bowel cancer is the second biggest cancer killer in the UK. Early detection significantly increases survival rates, reducing the need for intensive treatment and offering a high probability of a complete cure (around 90% for stage 1). That is why getting the right people into the right pathway quickly matters so much. The faecal immunochemical test (FIT) helps to do exactly that. It’s a simple at-home test that detects tiny amounts of blood in poo. Collecting the sample takes minutes.

Until recently, there have been limited treatment options for this type of ovarian cancer when it stops responding to standard chemotherapy treatment. Mirvetuximab soravtansine offers a new approach. Instead of chemotherapy, it uses a targeted therapy that seeks out a specific protein found on the surface of cancer cells and delivers a cancer-killing medicine directly to them. Women who took part in our evaluation highlighted the significant difference in how the 2 treatments affect daily life.

The device, known as a hybrid closed loop (HCL) system, automatically monitors blood sugar and delivers insulin through a small pump worn on the body. It removes the need for frequent finger prick tests and manual insulin injections. Ahead of Diabetes Awareness Week, an independent NICE committee has recommended that a pregnancy-specific version of this technology should be offered when planning a pregnancy. Managing blood sugar during pregnancy is difficult and critical.